The first and only oral JAK inhibitor approved for adults with active psoriatic arthritis1

Full Prescribing Information

Assisting with access and affordability for patients on XELJANZ and XELJANZ XR

In PsA, XELJANZ/XELJANZ XR should be used in combination with nonbiologic DMARDs.1

See full dosing here.

XELJANZ XR 11 mg administered once daily is pharmacokinetically equivalent to XELJANZ 5 mg administered twice daily. The recommended dose in patients with moderate to severe renal impairment and moderate hepatic impairment is XELJANZ 5 mg once daily.1

See additional dose adjustment information here.

DMARD=disease-modifying antirheumatic drug; JAK=Janus kinase; PsA=psoriatic arthritis.